JPMorgan raised the firm’s price target on Day One Biopharmaceuticals (DAWN) to $27 from $26 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharma’s Positive Q3 Earnings Call
- Strong Buy Recommendation for Day One Biopharmaceuticals Driven by Robust Financial Performance and Promising Drug Efficacy
- Positive Outlook for Day One Biopharmaceuticals: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating
- Day One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler
- Day One Biopharmaceuticals Reports Strong Q3 2025 Growth